
NASDAQHealthcareMedical - Instruments & Supplies
最新数据
US$57.28
+US$1.47 · +2.63%
AtriCure, Inc. creates, produces, and markets medical devices for the surgical treatment of cardiac tissue and intercostal nerves. Its market reach spans the United States, Europe, Asia, and other international territories. The company's product line features various ablation technologies. These include Isolator Synergy Clamps, which are single-use radiofrequency products. Its multifunctional pens, such as the MAX Pen, uniquely enable surgeons to evaluate cardiac arrhythmias, conduct temporary pacing, sensing, and stimulation, and perform tissue ablation with a single device. The Coolrail device facilitates the creation of longer linear ablation lines. For varying lengths of linear ablations, the CryoICE Cryoablation System is available. Furthermore, the EPi-Sense Guided Coagulation System is a single-use solution for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation. AtriCure also provides systems for cardiac appendage management and soft-tissue closure. The AtriClip System is an implantable device accompanied by a disposable applier, while the LARIAT System offers a suture-based solution for soft-tissue closure, compatible with various anatomical shapes. Additionally, AtriCure offers supplementary surgical tools including Lumitip Dissectors, designed to separate tissues for optimal access, Glidepath guides for precise clamp placement, and Subtle Cannulas facilitating access for EPi-Sense catheters. A suite of reusable cardiac surgery instruments, crucial for procedures involving heart valve repair or replacement, is also available. The company distributes its offerings through a combination of independent distributors and direct sales personnel. Founded in 2000, AtriCure maintains its headquarters in Mason, Ohio.
前收盘价
US$57.28
+US$1.47 · +2.63%
盘前
US$57.21
−US$0.07 · -0.12%
10月13日 7:12 ET
盘中时间采用ET。市场数据可能有所延迟。
AtriCure, Inc. creates, produces, and markets medical devices for the surgical treatment of cardiac tissue and intercostal nerves. Its market reach spans the United States, Europe, Asia, and other international territories. The company's product line features various ablation technologies. These include Isolator Synergy Clamps, which are single-use radiofrequency products. Its multifunctional pens, such as the MAX Pen, uniquely enable surgeons to evaluate cardiac arrhythmias, conduct temporary pacing, sensing, and stimulation, and perform tissue ablation with a single device. The Coolrail device facilitates the creation of longer linear ablation lines. For varying lengths of linear ablations, the CryoICE Cryoablation System is available. Furthermore, the EPi-Sense Guided Coagulation System is a single-use solution for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation. AtriCure also provides systems for cardiac appendage management and soft-tissue closure. The AtriClip System is an implantable device accompanied by a disposable applier, while the LARIAT System offers a suture-based solution for soft-tissue closure, compatible with various anatomical shapes. Additionally, AtriCure offers supplementary surgical tools including Lumitip Dissectors, designed to separate tissues for optimal access, Glidepath guides for precise clamp placement, and Subtle Cannulas facilitating access for EPi-Sense catheters. A suite of reusable cardiac surgery instruments, crucial for procedures involving heart valve repair or replacement, is also available. The company distributes its offerings through a combination of independent distributors and direct sales personnel. Founded in 2000, AtriCure maintains its headquarters in Mason, Ohio.
日内区间
当前US$57.28
52周区间
当前US$57.28
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目(USD) | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 5.35亿 USD | 4.65亿 USD | 3.99亿 USD | 3.3亿 USD | 2.74亿 USD |
| 销货成本 | 1.37亿 USD | 1.18亿 USD | 9887.5万 USD | 8443.9万 USD | 6846.9万 USD |
| 毛利 | 3.98亿 USD | 3.48亿 USD | 3亿 USD | 2.46亿 USD | 2.06亿 USD |
| 研究与开发 | 9016.8万 USD | 9617.8万 USD | 7391.5万 USD | 5733.7万 USD | 4850.6万 USD |
| 销售、一般及管理费用 | 3.11亿 USD | 2.91亿 USD | 2.53亿 USD | 2.31亿 USD | 2.05亿 USD |
| 营业费用 | 4.01亿 USD | 3.88亿 USD | 3.27亿 USD | 2.89亿 USD | 1.51亿 USD |
| 利息收入 | 447.9万 USD | 443.4万 USD | 379.2万 USD | 199.4万 USD | 46.6万 USD |
| 利息支出 | 587.8万 USD | 640.7万 USD | 692.5万 USD | 498.6万 USD | 491.8万 USD |
| 折旧和摊销 | 2053.1万 USD | 1873.3万 USD | 1481.3万 USD | 1171万 USD | 1044.1万 USD |
| 营业利润 | −344.7万 USD | −4001.3万 USD | −2668.3万 USD | −4266.9万 USD | 5520.5万 USD |
| 净利润 | −1144.8万 USD | −4469.8万 USD | −3043.8万 USD | −4646.6万 USD | 5019.9万 USD |
公司数据更新于 2026年10月13日。
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
第三方分析师预期可能变化,并非 GoAI 建议。
AI 生成内容及延迟市场数据仅供信息与教育用途,不构成投资建议。